knowledge -WSS

knowledge

author：focus 2025-09-28 15:06:40 - browse：97

President Joe Biden talks in the Roosevelt Room of the White House, in front of a painting of Theodore Roosevelt on a horse back — politics coverage from STAT — President Biden MANDEL NGAN/AFP via Getty Images

WASHINGTON — The White House is throwing its support behind a controversial authority that allows the government to undermine patent rights for certain high-priced medicines. It’s an early step that could have major ramifications for the American pharmaceutical industry, depending on whether and how federal officials actually use the authority.

The administration issued a framework for the National Institutes of Health to more broadly use so-called “march-in rights” — a policy that allows it to invalidate patent rights from drugmakers whose products rely on federally funded research. The framework lays out when the agency might assert this authority, and endorse using a drug’s price in that determination.

“We’ll make clear that when drug companies won’t sell taxpayer funded drugs at reasonable prices, we will be prepared to allow other companies to provide those drugs for less,” White House National Economic Advisor Lael Brainard told reporters. “These authorities are in existing laws, the last administration just didn’t want to allow them to be used in this way.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Readout Newsletter: Ironwood, Pfizer, FogPharma updates

WSS

AstraZeneca loses challenge to Medicare drug price negotiation

Kale crackers and hibiscus tea: My five days on a 'fasting diet'

RSV vaccines may be linked to small increased risk of developing GBS

Class action alleges UnitedHealth concealed DOJ probe

Why getting cancer drugs just got harder for rural patients

Welsh Carson private equity firm escapes from FTC antitrust case

focus

knowledge

explore

Peter Hotez and the public health issue of online harassment

How to address the problem of discarded donor organs

Tori Bowie and the unacceptable rates of Black maternal death

RaDonda Vaught to speak at CommonSpirit event on patient safety

Novavax promises a turnaround & Lilly roils the obesity market

FogPharma raises $145 million in rare Series E round

How to save PrEP access — and even expand it

Class action alleges UnitedHealth concealed DOJ probe

Psychedelics group wrestles with new pharma identity

How to fix the rural physician shortage in the U.S.

hotspot

Novel spinal cord stimulator treats paralysis without surgery

Welsh Carson private equity firm escapes from FTC antitrust case

Biotech companies concerned about China biosecurity crackdown

FDA does about

A Q&A with Aletha Maybank, AMA’s chief health equity officer

Flu vaccine offering decent levels of protection this winter, new data show

hotspot

Wikipedia

focus

focus